Kennelly B M
Br Heart J. 1977 May;39(5):540-6. doi: 10.1136/hrt.39.5.540.
The efficacy of quinidine versus lidoflazine therapy was compared in the maintenance of sinus rhythm after electrical cardioversion for atrial flutter or fibrillation in a group of 35 patients. Both quinidine and lidoflazine were relatively ineffective in maintaining sinus rhythm after cardioversion. Lidoflazine was also used to prevent supraventricular and ventricular tachycardias in a miscellaneous group of patients; one of these with paroxysmal supraventricular tachycardia developed runs of venttricular tachycardia soon after starting lidoflazine. The trial was stopped after 4 patients died while receiving lidoflazine, on the suspicion that their deaths may have been related to drug-induced arrhythmias. The arrhythmogenic potential of lidoflazine when used in patients with supraventricular arrhythmias constrasts with reports of its apparent safety in large numbers of patients with angina pectoris.
在一组35例患者中,比较了奎尼丁与利多氟嗪在心房扑动或颤动电复律后维持窦性心律方面的疗效。奎尼丁和利多氟嗪在复律后维持窦性心律方面相对无效。利多氟嗪还用于预防一组杂类患者的室上性和室性心动过速;其中一名阵发性室上性心动过速患者在开始使用利多氟嗪后不久出现室性心动过速发作。在4例接受利多氟嗪治疗的患者死亡后,该试验停止,怀疑他们的死亡可能与药物诱发的心律失常有关。利多氟嗪用于室上性心律失常患者时的致心律失常潜力与大量心绞痛患者中其明显安全性的报道形成对比。